Q2 earnings beats expectations, outlook better now: N. Maheshwari

Recent Q2 earnings reveal a mixed market outlook. Banking and financial services show strength. Tata Motors presents a varied performance, with electric vehicles positive but passenger vehicles facing hurdles. Information technology firms benefited from currency gains but may see challenges ahead. Investors should focus selectively on opportunities.

Metals likely to remain strong despite short-term dips: Rohit Srivastava

Indian stock markets are showing strong gains, led by the banking sector. Nifty remains above 25,900. Experts see continued momentum in banking, with NBFCs and PSU banks leading. Metals are also attractive for investors. Sector-specific rallies are driving market strength. Investors should watch key levels for Bank Nifty and Nifty.

IRB Infrastructure shares soar 7% on Rs 9,270 crore project win

IRB Infrastructure shares rose sharply on Monday after the company bagged NHAI’s Rs 9,270-crore TOT-17 project, its highest-valued 20-year monetisation award. The award covers 366 kilometres across the Lucknow–Ayodhya–Gorakhpur corridor on NH-27, along with a section of the Lucknow–Varanasi route on NH-731. The order win is being seen as a major boost to IRB’s portfolio, […]

Healthcare momentum strong, but selectivity key amid steep valuations: Nischal Maheshwari

Market expert Nischal Maheshwari shares insights on current market trends. He highlights growth companies and those ready for execution. Investors should be selective, especially in sectors with high valuations. Asian Paints is seen as a trading bounce. Healthcare offers earnings momentum but requires careful stock selection. Data centres present a nascent opportunity, with EPC contractors […]

Gold, silver prices open lower on hawkish US Fed commentary. What should you do?

Gold and silver slipped on Monday as traders booked profits after a strong global rally and hawkish Fed comments dampened hopes of a December rate cut. On MCX, gold fell 0.34% to ₹1,23,141 per 10g, while silver dropped 0.5% to ₹1,55,232 amid lingering inflation concerns and cautious Fed signals on further easing.

Alembic Pharmaceuticals shares rise 2% after USFDA nod for key hypertension drug

On Monday, Alembic Pharmaceuticals saw a surge in its stock prices after the USFDA greenlit its Diltiazem Hydrochloride Tablets, a crucial treatment for high blood pressure and angina. This pivotal approval brings the company’s total USFDA ANDA approvals to an impressive 230, highlighting its strong position in the pharmaceutical market.